Highlights
1 patent
About
Therapeutics for Neurodegenerative Diseases
Mitoconix Bio is developing a strategy for improving mitochondrial health as a disease-modifying therapeutic for neurodegenerative diseases. The companys lead drug is an inhibitor of pathological mitochondrial fragmentation and dysfunction. The drug has demonstrated in vivo efficacy in animal models of Huntingtons disease and Parkinsons disease, and it has shown beneficial activity in patient-derived cells of Huntingtons disease, sporadic and genetic Parkinsons disease, and sporadic and genetic Alzheimers disease.
Identity
| Name | Mitoconix Bio |
|---|---|
| Slug | mitoconix |
| Type / kind | startup |
| Crunchbase ID | mitoconix-bio |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwIe57McJDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Jul 2019 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | |
| HQ address | Ilan Ramon Street 2, Ness Ziona, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
pharmaceuticalsneurologyalzheimers-diseaseparkinson
Funding
| Total raised | $20.0M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}